| |
January 9-10, 2024 | San Francisco, CA January 16-18, 2024 | Virtual Driving the Future of Companion Diagnostics: Technology, Translational Medicine, & Commercialization in the Next Decade. Register today and Save $450!
|
|
Today’s Big NewsOct 30, 2023 |
| By Nick Paul Taylor Novartis’ $3.2 billion bet on Chinook Therapeutics is taking off. Top-line phase 3 data show the acquired candidate improved a sign of kidney disease, positioning the Swiss drugmaker to apply for accelerated approval from the FDA next year. |
|
|
|
By Nick Paul Taylor Merck KGaA is doubling down on its bet that PARPs are just getting started, paying 160 million euros ($169 million) for ex-China rights to a rival to Lynparza and Zejula. The outlay, which is backed by up to 1.4 billion euros in milestones, strengthens the German drugmaker’s hand in a cancer field targeted by AstraZeneca and Gilead. |
By Annalee Armstrong The TIGIT class is on a wild rollercoaster ride, dropping from mega heights, swerving around corners just barely hanging on and, at times, delivering thrills. And Roche is strapped into the first car, hanging on for the long haul. It’s paid off, says Charlie Fuchs, senior vice president and global head of oncology and hematology drug development at Genentech and Roche. |
Sponsored by Medidata The clinical trial landscape has seen a seismic shift in recent years, spurred by technology-driven data collection. Yet there are some opportunities… |
|
Convert more DNA into sequenceable library for enhanced sensitivity — particularly with cfDNA samples and ctDNA detection. Prepare highly complex libraries in under 2 hours from as little as 500 pg. Explore the data.
|
|
By Annalee Armstrong Moderna is shifting attention to the next pandemic, whatever it may be, in a new partnership with the Coalition for Epidemic Preparedness Innovations to condense vaccine development timelines down to 100 days. |
By Max Bayer More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. |
By Gabrielle Masson Investor Abingworth has closed a new $356 million fund specifically designed to co-develop late-stage clinical programs with biotechs and pharmas. |
By Fraiser Kansteiner Following prior cuts in Illinois and Colorado, Pfizer is parting ways with a staggering 791 employees in Gladstone, New Jersey, according to a Worker Adjustment and Retraining Notification alert from the Garden State. |
By Conor Hale Though Philips has argued its U.S. subsidiary should be responsible for paying damages in its massive CPAP machine recall, instructions to continue selling home ventilators came from the parent company’s top leadership, according to ProPublica and the Pittsburgh Post-Gazette. |
By Nick Paul Taylor A group of pharmacy benefit managers has split off from the pack, launching a “six-figure digital media campaign” to make the case that some of the widely criticized organizations provide value to the healthcare system. |
By Andrea Park As it continues to take advantage of the hole left in the CPAP market by Philips’ ongoing recall, ResMed is still fine-tuning its long-term growth strategy—a process that’s now resulting in short-term shrinkage. |
By Noah Tong Deemed a significant advancement for music as medicine treatment, a new partnership will provide members in skilled nursing facilities with access to therapeutic health platform SingFit. |
By Ben Adams Canadian former professional ice hockey player Wayne Gretzky engages in a conversation with an AI-generated, younger version of himself, who aims to warn him about the dangers of RSV in a new ad. |
Fierce podcastsDon’t miss an episode |
| In this episode of “The Top Line,” we delve into the FDA's controversial approval of Aduhelm, a drug for Alzheimer's disease, despite an independent advisory committee's resounding rejection. The decision has sparked questions about potential bias within the regulatory body. |
|
|---|
|
|
| WebinarEmbark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperCell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| |
|
